Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 13.95B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 32.56%.
Undervalued
The company’s latest PE is 23.89, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 88.74M shares, increasing 5.91% quarter-over-quarter.
Held by Wallace Weitz
Star Investor Wallace Weitz holds 102.34K shares of this stock.